208 related articles for article (PubMed ID: 26695380)
1. Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) men.
de Carvalho TM; Heijnsdijk EA; de Koning HJ
Int J Cancer; 2016 May; 138(10):2522-8. PubMed ID: 26695380
[TBL] [Abstract][Full Text] [Related]
2. Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study.
de Carvalho TM; Heijnsdijk EA; de Koning HJ
BJU Int; 2017 Apr; 119(4):560-566. PubMed ID: 27222299
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
4. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
5. Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.
Mühlberger N; Boskovic K; Krahn MD; Bremner KE; Oberaigner W; Klocker H; Horninger W; Sroczynski G; Siebert U
BMC Public Health; 2017 Jun; 17(1):596. PubMed ID: 28651567
[TBL] [Abstract][Full Text] [Related]
6. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly.
van den Bergh RC; Roemeling S; Roobol MJ; Aus G; Hugosson J; Rannikko AS; Tammela TL; Bangma CH; Schröder FH
Eur Urol; 2009 Jan; 55(1):1-8. PubMed ID: 18805628
[TBL] [Abstract][Full Text] [Related]
8. When should active surveillance for prostate cancer stop if no progression is detected?
de Carvalho TM; Heijnsdijk EAM; de Koning HJ
Prostate; 2017 Jun; 77(9):962-969. PubMed ID: 28419541
[TBL] [Abstract][Full Text] [Related]
9. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.
Van Hemelrijck M; Garmo H; Lindhagen L; Bratt O; Stattin P; Adolfsson J
Eur Urol; 2017 Oct; 72(4):534-541. PubMed ID: 27816297
[TBL] [Abstract][Full Text] [Related]
10. Overtreatment of men with low-risk prostate cancer and significant comorbidity.
Daskivich TJ; Chamie K; Kwan L; Labo J; Palvolgyi R; Dash A; Greenfield S; Litwin MS
Cancer; 2011 May; 117(10):2058-66. PubMed ID: 21523717
[TBL] [Abstract][Full Text] [Related]
11. Aligning evidence and practice: future research needs to increase utilization of active surveillance for favorable risk prostate cancer.
Carter HB
Curr Opin Urol; 2015 May; 25(3):277-82. PubMed ID: 25692722
[TBL] [Abstract][Full Text] [Related]
12. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
[TBL] [Abstract][Full Text] [Related]
13. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
14. Gleason 6 Prostate Cancer: Translating Biology into Population Health.
Eggener SE; Badani K; Barocas DA; Barrisford GW; Cheng JS; Chin AI; Corcoran A; Epstein JI; George AK; Gupta GN; Hayn MH; Kauffman EC; Lane B; Liss MA; Mirza M; Morgan TM; Moses K; Nepple KG; Preston MA; Rais-Bahrami S; Resnick MJ; Siddiqui MM; Silberstein J; Singer EA; Sonn GA; Sprenkle P; Stratton KL; Taylor J; Tomaszewski J; Tollefson M; Vickers A; White WM; Lowrance WT
J Urol; 2015 Sep; 194(3):626-34. PubMed ID: 25849602
[TBL] [Abstract][Full Text] [Related]
15. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
[TBL] [Abstract][Full Text] [Related]
16. Gleason score, age and screening: modeling dedifferentiation in prostate cancer.
Draisma G; Postma R; Schröder FH; van der Kwast TH; de Koning HJ
Int J Cancer; 2006 Nov; 119(10):2366-71. PubMed ID: 16858675
[TBL] [Abstract][Full Text] [Related]
17. Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer.
Liu J; Womble PR; Merdan S; Miller DC; Montie JE; Denton BT;
Urology; 2015 Nov; 86(5):901-5. PubMed ID: 26358397
[TBL] [Abstract][Full Text] [Related]
18. Observational studies and the natural history of screen-detected prostate cancer.
Albertsen PC
Curr Opin Urol; 2015 May; 25(3):232-7. PubMed ID: 25692723
[TBL] [Abstract][Full Text] [Related]
19. Expectant management for men with early stage prostate cancer.
Filson CP; Marks LS; Litwin MS
CA Cancer J Clin; 2015; 65(4):265-82. PubMed ID: 25958817
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis of active surveillance for localized prostate cancer.
Kim S; Dall'Era MA; Evans CP
Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
